ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2630

Low Medication Adherence Is Observed In Behcet’s Disease

Gonca Mumcu1, Ali Taze2, Esra Kula2, Semiha Yemez2, Silay Eksi2, Leyla Köksal3, Fatma Alibaz-Oner4, Sibel Yilmaz Oner4, Pamir Atagündüz4, Nevsun Inanc5, Tülin Ergun6 and Haner Direskeneli4, 1Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, 2Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, 3Marmara University, Faculty of Health Sciences, Istanbul, Turkey, 4Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 5Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, 6Dermatology, Marmara University, School of Medicine, Istanbul, Turkey

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome and medication

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis III

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Symptom-control with reduction of mortality and morbidityare the main treatment goalsin Behcet’s Disease (BD). However, similar to other chronic disorders,  increased unnecessary visits, hospitalisation and medication costs are thought to originate from lack of adherence to medications of the treatment protocols in BD. Therefore, the aim of this study was to evaluate self-reported medication adherence in BD patients.

Methods:

The study group was composed of 118BD patients(F/M:62/56, mean age:37.7±10.8 years) and disease control groups regarding 50 patients with Rheumatoid Arthritis (RA, F/M:37/13, mean age:39.9±10.4 years) and 58 patients with Familial Mediterranean Fever (FMF, F/M:39/19, mean age:34.4±11.9 years).

Medication adherence was evaluated by the Morisky scale that is a brief 4-item structured questionnaire. Each patient has a scale score ranging from “0” to “4” with low scores indicating better adherence.Trained interviewers (n=4) who were not involved in any disease assessment or treatmenthelped to individuals with visual impairment or illiterates in filling the questionnaire.

Results:

The Moriskyscale score was similar in BD (2.05±0.99) and FMF (2.01±1.1) (p=0.99), whereas it was significantly lower in RA (1.54±1.05) than BD (p=0.021).In BD, no significant difference was present in the Morisky scale score according to gender (females:2.09±0.9vsmales:2.0±1.02, p=0.60).The score of patients with major organ involvement (2.1±1.1) was also similar to mucocutaneous ones (1.9±0.9) (p=0.57) in males. In contrast, the score was lower in patients with major organ involvement (1.7±1.1) compared to patients with mucocutaneous involvement (2.29±0.8) in female BD patients (p=0.04). Moreover, a weak correlation was observed between the Morisky scale score and the number of medication (4.8±2.4, r:0.3 p=0.029).

Conclusion:

Self-reported medication adherence was found to be low in BD patients. Medication adherence seems to be different according to gender in the frame of major organ involvement, suggesting that either the perception or consequences of disease-associated morbidity is associated to gender-related features in BD.


Disclosure:

G. Mumcu,
None;

A. Taze,
None;

E. Kula,
None;

S. Yemez,
None;

S. Eksi,
None;

L. Köksal,
None;

F. Alibaz-Oner,
None;

S. Yilmaz Oner,
None;

P. Atagündüz,
None;

N. Inanc,
None;

T. Ergun,
None;

H. Direskeneli,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-medication-adherence-is-observed-in-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology